Better preservation of the peritoneum in rats exposed to amino acid-based peritoneal dialysis fluid

Peritoneal Dialysis International

Volumn 25, Issue 1, 2005, Pages 58-67

  Zareie, Mohammad ^a   van Lambalgen, Anton A ^a   ter Wee, Piet M ^a   Hekking, Liesbeth H P ^a   Keuning, Eelco D ^a   Schadee Eestermans, Inge L ^a   Faict, Dirk ^b   Degréve, Bart ^b   Tangelder, Geert Jan ^a   Beelen, Robert H J ^a   van den Born, Jacob ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Baxter R and D   (Belgium)

Author keywords

Amino acid based PDF; Conventional glucose containing PDF; Mesothelium; Microcirculation; Morphology; Rats

Indexed keywords

DIANEAL; NUTRINEAL; PERITONEAL DIALYSIS FLUID;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INTERACTION; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; ELECTRON MICROSCOPE; ENDOTHELIUM; FIBROSIS; IMMUNE DEFICIENCY; LEUKOCYTE; LEUKOCYTE COUNT; MALE; MESENTERY; MESENTERY BLOOD VESSEL; MESOTHELIUM CELL; MICROCIRCULATION; MICROSCOPY; MORPHOLOGY; MORPHOMETRICS; NONHUMAN; OMENTUM; PERITONEAL CATHETER; PERITONEAL DIALYSIS; PERITONEAL DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; STATISTICAL ANALYSIS; VASCULAR ACCESS; VENULE;

EID: 20144371445     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080502500112     Document Type: Article

References (31)

1. Davies SJ, Phillips L, Naish PF, Russell GI. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 2001; 12:1046-51.
2. Ha H, Lee HB. Effect of high glucose on peritoneal mesothelial cell biology. Perit Dial Int 2000; 20(Suppl 2):S15-18.
3. Schalkwijk CG, Posthuma N, ten Brink HJ, ter Wee PM, Teerlink T. Induction of 1,2-dicarbonyl compounds, intermediates in the formation of advanced glycation end-products, during heat-sterilization of glucose-based peritoneal dialysis fluids. Perit Dial Int 1999; 19:325-33.
4. Honda K, Nitta K, Horita S, Yumura W, Nihei H, Nagai R, et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 1999; 14:1541-9.
5. Okamoto T, Tanaka S, Stan AC, Koike T, Kase M, Makita Z, et al. Advanced glycation end products induce angiogenesis in vivo. Microvasc Res 2002; 63:186-95.
6. Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M. Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta over-expression in proximal tubular cells. Kidney Int 2003; 63:464-73.
7. Wieslander AP, Deppisch R, Svensson E. In vitro biocompatibility of a heat-sterilized, low-toxic, and less acidic fluid for peritoneal dialysis. Perit Dial Int 1995; 15:158-64.
8. Jorres A, Bender TO, Finn A, Witowski J, Frohlich S, Gahl GM, et al. Biocompatibility and buffers: effect of bicarbonate-buffered peritoneal dialysis fluids on peritoneal cell function. Kidney Int 1998; 54:2184-93.
9. Pecoits-Filho R, Mujais S, Lindholm B. Future of icodextrin as an osmotic agent in peritoneal dialysis. Kidney Int Suppl 2002; 81:S80-7.
10. Smit W, de Waart DR, Struijk DG, Krediet RT. Peritoneal transport characteristics with glycerol-based dialysate in peritoneal dialysis. Perit Dial Int 2000; 20:557-65.
11. Jones MR, Gehr TW, Burkart JM, Hamburger RJ, Kraus AP Jr, Piraino BM, et al. Replacement of amino acid and protein Losses with 1.1% amino acid peritoneal dialysis solution. Perit Dial Int 1998; 18:210-16.
12. Lindholm B, Park MS, Bergstrom J. Supplemented dialysis: amino acid-based solutions in peritoneal dialysis. Contrib Nephrol 1993; 103:168-82.
13. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996; 94:2743-8.
14. Douma CE, de Waart DR, Struijk DG, Krediet RT. Effect of amino acid based dialysate on peritoneal blood flow and permeability in stable CAPD patients: a potential rote for nitric oxide? Clin Nephrol 1996; 45:295-302.
15. Plum J, Fussholler A, Schoenicke G, Busch T, Erren C, Fieseler C, et al. In vivo and in vitro effects of amino-acid-based and bicarbonate-buffered peritoneal dialysis solutions with regard to peritoneal transport and cytokines/prostanoids dialysate concentrations. Nephrol Dial Transplant 1997; 12:1652-60.
16. Li FK, Chan LY, Woo JC, Ho SK, Lo WK, Lai KN, et al. A 3-year, prospective, randomized, controlled study on amino acid dialysate in patients on CAPD. Am J Kidney Dis 2003; 42:173-83.
17. Taylor GS, Patel V, Spencer S, Fluck RJ, McIntyre CW. Long-term use of 1.1% amino acid dialysis solution in hypoalbuminemic continuous ambulatory peritoneal dialysis patients. Clin Nephrol 2002; 58:445-50.
18. Jones M, Gahl GM, Ludat K. In vitro biocompatibility evaluation of a novel bicarbonate-buffered amino-acid solution for peritoneal dialysis. Nephrol Dial Transplant 1997; 12:543-9.
19. Zareie M, van Lambalgen AA, De Vriese AS, Van Gelderop E, Lameire N, ter Wee PM, et al. Increased leukocyte rolling in newly formed mesenteric vessels in the rat during peritoneal dialysis. Perit Dial Int 2002; 22:655-62.
20. Hekking LH, Zareie M, Driesprong BA, Faict D, Welten AGA, De Greeuw I, et al. Better preservation of peritoneal morphologic features and defense in rats after long-term exposure to a bicarbonate/lactate-buffered solution. J Am Soc Nephrol 2001; 12:2775-86.
21. Intaglietta M, Tompkins WR. Microvascular measurements by video image shearing and splitting. Microvasc Res 1973; 5:309-12.
22. Doherty NS, Griffiths RJ, Hakkinen JP. Post-capillary venules in the milky spots of the greater omentum are the major site of plasma protein and leukocyte extravasation in rodent models of peritonitis. Inflamm Res 1995; 44:169-77.
23. Zareie M, Hekking LHP, Welten AGA, Driesprong BAJ, Schadee-Eestermans IL, Faict D, et al. Contribution of lactate buffer, glucose and glucose degradation end products to peritoneal injury in vivo. Nephrol Dial Transplant 2003; 18:2629-37.
24. Beelen RH, Hekking LH, Zareie M, Van den Born J. Rat models in peritoneal dialysis. Nephrol Dial Transplant 2001; 16:672-4.
25. Mortier S, De Vriese AS, McLoughlin RM, Topley N, Schaub TP, Passlick-Deetjen J, et al. Effects of conventional and new peritoneal dialysis fluids on leukocyte recruitment in the rat peritoneal membrane. J Am Soc Nephrol 2003; 14:1296-306.
26. Welten AGA, Zareie M, van den Born J, ter Wee PM, Schalkwijk CG, Driesprong BAJ, et al. In vitro and in vivo models for peritonitis demonstrate unchanged neutrophil migration after exposure to dialysis fluids. Nephrol Dial Transplant 2004; 19:831-9.
27. ter Wee PM, Beelen RHJ, van den Born J. The application of animal models to study the biocompatibility of bicarbonate-buffered peritoneal dialysis solutions. Kidney Int Suppl 2003; 88:S75-83.
28. Inagi R, Miyata T, Yamamoto T, Suzuki D, Urakami K, Saito A, et al. Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis. FEBS Lett 1999; 17:260-4.
29. Ha H, Cha MK, Choi HN, Lee HB. Effects of peritoneal dialysis solutions on the secretion of growth factors and extracellular matrix proteins by human peritoneal mesothelial cells. Perit Dial Int 2002; 22:171-7.
30. Chan TM, Leung JK, Sun Y, Lai KN, Tsang RC, Yung S. Different effects of amino acid-based and glucose-based dialysate from peritoneal dialysis patients on mesothelial cell ultrastructure and function. Nephrol Dial Transplant 2003; 18:1086-94.
31. Schalkwijk CG, ter Wee PM, Teerlink T. Reduced 1,2-dicarbonyl compounds in bicarbonate-buffered peritoneal dialysis (PD) fluids and PD fluids based glucose polymers or amino acids. Perit Dial Int 2000; 20:796-8.